These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 28646172)

  • 1. Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells.
    Momeny M; Zarrinrad G; Moghaddaskho F; Poursheikhani A; Sankanian G; Zaghal A; Mirshahvaladi S; Esmaeili F; Eyvani H; Barghi F; Sabourinejad Z; Alishahi Z; Yousefi H; Ghasemi R; Dardaei L; Bashash D; Chahardouli B; Dehpour AR; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Sci Rep; 2017 Jun; 7(1):4204. PubMed ID: 28646172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
    Momeny M; Esmaeili F; Hamzehlou S; Yousefi H; Javadikooshesh S; Vahdatirad V; Alishahi Z; Mousavipak SH; Bashash D; Dehpour AR; Tavangar SM; Tavakkoly-Bazzaz J; Haddad P; Kordbacheh F; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Cell Oncol (Dordr); 2019 Aug; 42(4):491-504. PubMed ID: 31025257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR Blockade Reverses Cisplatin Resistance in Human Epithelial Ovarian Cancer Cells.
    Poursheikhani A; Yousefi H; Tavakoli-Bazzaz J; Seyed H G
    Iran Biomed J; 2020 Nov; 24(6):370-8. PubMed ID: 32660222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.
    Ather F; Hamidi H; Fejzo MS; Letrent S; Finn RS; Kabbinavar F; Head C; Wong SG
    PLoS One; 2013; 8(2):e56112. PubMed ID: 23405260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells.
    Momeny M; Eyvani H; Barghi F; Ghaffari SH; Javadikooshesh S; Hassanvand Jamadi R; Esmaeili F; Alishahi Z; Zaghal A; Bashash D; Samani FS; Ghaffari P; Dehpour AR; Tavangar SM; Alimoghaddam K; Ghavamzadeh A
    Anticancer Drugs; 2018 Nov; 29(10):1011-1020. PubMed ID: 30096128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells.
    Momeny M; Sabourinejad Z; Zarrinrad G; Moghaddaskho F; Eyvani H; Yousefi H; Mirshahvaladi S; Poursani EM; Barghi F; Poursheikhani A; Dardaei L; Bashash D; Ghazi-Khansari M; Tavangar SM; Dehpour AR; Yaghmaie M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Sci Rep; 2017 Apr; 7():45954. PubMed ID: 28383032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway.
    Momeny M; Ghasemi R; Valenti G; Miranda M; Zekri A; Zarrinrad G; Javadikooshesh S; Yaghmaie M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Tumour Biol; 2016 Mar; 37(3):3913-23. PubMed ID: 26482609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.
    Parashar D; Nair B; Geethadevi A; George J; Nair A; Tsaih SW; Kadamberi IP; Gopinadhan Nair GK; Lu Y; Ramchandran R; Uyar DS; Rader JS; Ram PT; Mills GB; Pradeep S; Chaluvally-Raghavan P
    Cancer Res; 2020 Dec; 80(24):5554-5568. PubMed ID: 33087324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
    Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
    Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of nuclear factor-κB (NF-κB) pathway inhibits growth and induces apoptosis in chemoresistant ovarian carcinoma cells.
    Momeny M; Yousefi H; Eyvani H; Moghaddaskho F; Salehi A; Esmaeili F; Alishahi Z; Barghi F; Vaezijoze S; Shamsaiegahkani S; Zarrinrad G; Sankanian G; Sabourinejad Z; Hamzehlou S; Bashash D; Aboutorabi ES; Ghaffari P; Dehpour AR; Tavangar SM; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Int J Biochem Cell Biol; 2018 Jun; 99():1-9. PubMed ID: 29567488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α2,3-sialyltransferase type I regulates migration and peritoneal dissemination of ovarian cancer cells.
    Wen KC; Sung PL; Hsieh SL; Chou YT; Lee OK; Wu CW; Wang PH
    Oncotarget; 2017 Apr; 8(17):29013-29027. PubMed ID: 28423672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dacomitinib, a new pan-EGFR inhibitor, is effective in killing ovarian cancer cells.
    Xu L; Wu H; Jiang C; Wang H; Gao B; Yan S; Qi Y; Zhou S
    Discov Med; 2016 Nov; 22(122):297-309. PubMed ID: 28009971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct apoptotic blocks mediate resistance to panHER inhibitors in HER2+ breast cancer cells.
    Karakas B; Ozmay Y; Basaga H; Gul O; Kutuk O
    Biochim Biophys Acta Mol Cell Res; 2018 Aug; 1865(8):1073-1087. PubMed ID: 29733883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer.
    Zhang P; Zhang P; Zhou M; Jiang H; Zhang H; Shi B; Pan X; Gao H; Sun H; Li Z
    Carcinogenesis; 2013 Nov; 34(11):2639-46. PubMed ID: 23764753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.
    Roberts CM; Tran MA; Pitruzzello MC; Wen W; Loeza J; Dellinger TH; Mor G; Glackin CA
    Sci Rep; 2016 Nov; 6():37652. PubMed ID: 27876874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
    Yue P; Zhang X; Paladino D; Sengupta B; Ahmad S; Holloway RW; Ingersoll SB; Turkson J
    Oncogene; 2012 May; 31(18):2309-22. PubMed ID: 21909139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
    Gui T; Shen K
    Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor activity of neratinib, a pan-HER inhibitor, in gastric adenocarcinoma cells.
    Hamzehlou S; Momeny M; Zandi Z; Kashani B; Yousefi H; Dehpour AR; Tavakkoly-Bazzaz J; Ghaffari SH
    Eur J Pharmacol; 2019 Nov; 863():172705. PubMed ID: 31574259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.
    Grivas PD; Day KC; Karatsinides A; Paul A; Shakir N; Owainati I; Liebert M; Kunju LP; Thomas D; Hussain M; Day ML
    Mol Med; 2013 Nov; 19(1):367-76. PubMed ID: 24166682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.